IRIS
MONDELLO, Patrizia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.887
EU - Europa 2.234
AS - Asia 1.698
SA - Sud America 683
AF - Africa 45
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 7.551
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.824
SG - Singapore 733
BR - Brasile 608
IE - Irlanda 529
CN - Cina 465
SE - Svezia 404
PL - Polonia 311
IT - Italia 276
HK - Hong Kong 230
DE - Germania 192
FI - Finlandia 123
GB - Regno Unito 111
UA - Ucraina 109
VN - Vietnam 100
RU - Federazione Russa 62
IN - India 32
FR - Francia 29
CA - Canada 27
MX - Messico 24
AR - Argentina 23
NL - Olanda 21
BE - Belgio 20
JP - Giappone 18
EC - Ecuador 17
ID - Indonesia 17
BD - Bangladesh 16
TR - Turchia 15
AT - Austria 13
IQ - Iraq 13
MA - Marocco 12
ES - Italia 10
UZ - Uzbekistan 10
ZA - Sudafrica 10
CO - Colombia 8
JO - Giordania 8
PY - Paraguay 8
PE - Perù 7
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
KE - Kenya 5
TN - Tunisia 5
AZ - Azerbaigian 4
IR - Iran 4
PK - Pakistan 4
VE - Venezuela 4
AL - Albania 3
AM - Armenia 3
CL - Cile 3
DZ - Algeria 3
EG - Egitto 3
IL - Israele 3
JM - Giamaica 3
LT - Lituania 3
NP - Nepal 3
OM - Oman 3
PA - Panama 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EE - Estonia 2
LB - Libano 2
MY - Malesia 2
NI - Nicaragua 2
RO - Romania 2
SA - Arabia Saudita 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
CR - Costa Rica 1
GE - Georgia 1
HN - Honduras 1
IS - Islanda 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LV - Lettonia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TM - Turkmenistan 1
TW - Taiwan 1
Totale 7.551
Salva come PNG Salva come JPEG
Città #
Dublin 529
Chandler 404
Ashburn 382
Singapore 336
Dallas 326
Warsaw 311
Nyköping 239
Hong Kong 229
Beijing 167
Jacksonville 161
Messina 147
Munich 126
Dearborn 98
Princeton 83
Los Angeles 81
Medford 73
The Dalles 64
Des Moines 60
Ann Arbor 58
Cambridge 52
Lancaster 52
Helsinki 51
New York 50
Houston 41
São Paulo 36
Wilmington 34
Boardman 33
Redondo Beach 31
Woodbridge 28
Seattle 27
Buffalo 26
Jinan 25
Dong Ket 24
Rio de Janeiro 23
San Mateo 23
Ho Chi Minh City 22
Shenyang 22
Moscow 20
Brussels 18
Falls Church 18
Hanoi 18
Tianjin 17
Turku 16
Nuremberg 15
Jakarta 14
Tokyo 14
Belo Horizonte 13
Chicago 12
Montreal 12
Nanchang 12
Nanjing 12
Ningbo 12
Brasília 11
Santa Clara 11
Tashkent 10
Brooklyn 9
Milan 9
Porto Alegre 9
Rome 9
Boston 8
Chennai 8
Curitiba 8
Haikou 8
Shenzhen 8
Zhengzhou 8
Amman 7
Atlanta 7
Baghdad 7
Campinas 7
Guangzhou 7
Hangzhou 7
Hải Dương 7
Kunming 7
Lappeenranta 7
Stockholm 7
Vienna 7
Washington 7
Aracaju 6
Auburn Hills 6
Columbus 6
Fairfield 6
Florianópolis 6
London 6
Mexico City 6
Pune 6
Quito 6
Redwood City 6
Santo André 6
Taizhou 6
Abidjan 5
Amsterdam 5
Changsha 5
Chengdu 5
Contagem 5
Council Bluffs 5
Cuenca 5
Da Nang 5
Dhaka 5
Goiânia 5
Hebei 5
Totale 5.024
Salva come PNG Salva come JPEG
Nome #
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. 256
De novo mutation in SLC25A22 gene: expansion of the clinical and electroencephalographic phenotype 232
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 157
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? 154
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 146
Emerging markers of cachexia predict survival in cancer patients. 143
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 142
Kinase regulation of human MHC class i molecule expression on cancer cells 141
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 139
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 135
90 Y-ibritumomab tiuxetan: A nearly forgotten opportunity 126
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. 119
Efficacy of Intravenous Hydrocortisone Treatment in Refractory Neonatal Seizures: A Report on Three Cases 119
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 117
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 114
null 111
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 110
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 108
null 107
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 105
null 105
null 105
Thyroid function, autoimmunity and nodules in hematological malignancies 104
Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach 103
Complications of trauma patients admitted to the ICU in level i academic trauma centers in the United States 102
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. 100
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 99
null 99
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients 98
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 97
null 96
null 95
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma 95
Congenital heart disease in down syndrome 94
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 93
null 93
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. 92
The heart in Anderson-Fabry disease 91
null 90
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 90
Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. 88
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 87
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 86
Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice 84
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 83
Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats 82
Treatment of Aggressive B Cell Lymphomas: Updates in 2019 82
null 81
Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model 81
Palmitoylethanolamide Reduces Early Renal Dysfunction and Injury Caused by Experimental Ischemia and Reperfusion in Mice. 81
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 79
null 79
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 79
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 78
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies 77
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. 76
null 75
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 75
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP 74
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma 72
null 72
Effects of Apocynin, A Nadph-oxidase Inhibitor, In Contrast-induced Nephropathy 70
null 67
null 66
null 64
PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB 63
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma 63
Emerging drugs for diffuse large B-cell lymphoma. 62
Primary central nervous system lymphoma: Novel precision therapies 61
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma 56
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study 56
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse 56
Insights into the tumor microenvironment of B cell lymphoma 49
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy 49
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma 49
Pim kinases in hematological malignancies: where are we now and where are we going? 47
null 46
Questionable Validity of Cardiac Risk Score on the Basis of the NSABP B-31 Model 42
null 41
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis 36
null 35
Silencing GNAS enhances HDAC3i efficacy in CREBBP wild type B cell lymphoma 35
Simplified risk stratification model for patients with Waldenström macroglobulinemia 35
null 33
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL 27
null 24
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma 19
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study 18
Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation 17
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma 15
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 15
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma 15
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 15
Harnessing the Molecular Fingerprints of B Cell Lymphoma for Precision Therapy 15
Multi-omics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation 13
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts 13
Biosimilar Erythropoietin Alpha Is Effective As Originator Erythropoietin Alpha Plus Liposomial Iron and B12 and Folates in Patients with Refractory Anemia: A Retrospective Real-Life Approach 13
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 12
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype 12
Fatal Hepatocellular Carcinoma in a Patient with Occult Hepatitis B Virus Infection following the Administration of R-CHOP for Diffuse Large B-Cell Lymphoma. 10
Totale 7.827
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.568
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.568
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021338 0 0 0 0 0 40 40 80 56 70 20 32
2021/2022560 3 45 19 19 30 19 20 19 8 104 66 208
2022/20231.490 136 128 85 119 91 141 14 80 628 18 37 13
2023/2024331 23 53 22 26 20 57 18 33 5 23 20 31
2024/20251.865 14 19 34 118 103 82 118 418 414 132 142 271
2025/20261.917 216 333 376 423 511 58 0 0 0 0 0 0
Totale 7.921